The Providence Cancer Center MITCI study has been expanded to allow up to 70 patients to enroll, after the combination of two immunotherapy treatments achieved a 77 percent disease-control rate in patients with advanced melanoma.  Principal investigator Brendan Curti, M.D. , co-director of the Providence Cancer Center Melanoma Program, presented the preliminary results at the 2017 annual meeting of the American Association for Cancer Research in April.

 

Included in the trial were several patients who had been treated previously with immune checkpoint inhibitors  and had become resistant to the approach. The combination treatment appeared to overcome that resistance.  In addition, side effects were minimal.

 

Patients in the study receive both an investigational formulation of CVA21 (CAVATAK), an immunotherapy based on a common cold virus, and ipilimumab (Yervoy), an FDA-approved immunotherapy.  Of 22 patients evaluated to date, four  have had a complete response, seven  have had a partial response and six  have stable disease.

Enrollment in the expanded study is ongoing.  View trial information here .

Read more about this study. 

 

This featured study is one of 12 melanoma studies currently open at Providence Cancer Center. To see all open melanoma studies, click here.  To see all studies in all cancer types, click here .